Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Lawrence

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Wellcome Open Research|October 3, 2025
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA)Victoria Babirye Tumusiime, Eugene Ruzagira, Claire Norcross, et al.
The Lancet. Microbe|February 11, 2024
Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy studyTshepiso Mbangiwa, Aude Sturny-Leclère, Kwana Lechiile, et al.
Medicine|October 8, 2020
Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in BotswanaNametso Kelentse, Sikhulile Moyo, Mompati Mogwele, et al.
The Lancet. HIV|September 7, 2025
Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trialJayne Ellis, Elisabetta Groppelli, Ronan Doyle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2024
Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort StudyJane Gakuru, Enock Kagimu, Biyue Dai, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 2023
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitisKatharine E Stott, Ajisa Ahmadu, Cheusisime Kajanga, et al.
The Lancet. Global Health|October 20, 2023
Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trialJoseph N Jarvis, Roger Chou, Thomas S Harrison, et al.
Open Forum Infectious Diseases|July 27, 2022
Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective CohortLillian Tugume, Ann Fieberg, Kenneth Ssebambulidde, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2026
Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in MalawiMary Feser, Thulani Maphosa, Amir Shroufi, et al.
Open Forum Infectious Diseases|April 24, 2025
Relative Contribution of Pharmacokinetics and Immune Signatures to Clinical Outcomes in Patients With HIV-associated Cryptococcal MeningitisKatharine E Stott, Dumizulu Tembo, Cheusisime Kajanga, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Wellcome Open Research|October 3, 2025
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA)Victoria Babirye Tumusiime, Eugene Ruzagira, Claire Norcross, et al.
The Lancet. Microbe|February 11, 2024
Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy studyTshepiso Mbangiwa, Aude Sturny-Leclère, Kwana Lechiile, et al.
Medicine|October 8, 2020
Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in BotswanaNametso Kelentse, Sikhulile Moyo, Mompati Mogwele, et al.
The Lancet. HIV|September 7, 2025
Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trialJayne Ellis, Elisabetta Groppelli, Ronan Doyle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2024
Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort StudyJane Gakuru, Enock Kagimu, Biyue Dai, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 2023
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitisKatharine E Stott, Ajisa Ahmadu, Cheusisime Kajanga, et al.
The Lancet. Global Health|October 20, 2023
Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trialJoseph N Jarvis, Roger Chou, Thomas S Harrison, et al.
Open Forum Infectious Diseases|July 27, 2022
Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective CohortLillian Tugume, Ann Fieberg, Kenneth Ssebambulidde, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2026
Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in MalawiMary Feser, Thulani Maphosa, Amir Shroufi, et al.
Open Forum Infectious Diseases|April 24, 2025
Relative Contribution of Pharmacokinetics and Immune Signatures to Clinical Outcomes in Patients With HIV-associated Cryptococcal MeningitisKatharine E Stott, Dumizulu Tembo, Cheusisime Kajanga, et al.
Pageof 16